-
Identifying Patients Who Will Benefit From Intensified Prostate Cancer Treatment
12 Jul 2025 14:00 GMT
… intensified treatment? What have recent trials like STAMPEDE shown about adding Zytiga (abiraterone … standard treatment plus two years of a hormone therapy drug called Zytiga. Zytiga is … on my own trial, STAMPEDE, and a second trial called LATITUDE, we …
-
Considering the Treatment of mHSPC with Oral Therapies
11 Jul 2025 20:00 GMT
… Specialists, highlighted treatment optimization and clinical trial insights in … well controlled with medication
No family history … therapy [ADT]: abiraterone [Zytiga], apalutamide [Erleada], and enzalutamide … landmark trials led to approval of oral drugs in …
-
FDA grants breakthrough device designation for ArteraAI Prostate tool
10 Jul 2025 16:42 GMT
… intelligence (AI) “precision medicine tool intended to assist clinicians … data from the STAMPEDE trial (NCT00268476), investigators found … addition of abiraterone acetate (Zytiga) plus prednisone to … do well from standard treatment alone—hormone therapy and …
-
FDA and EMA authorize phase 3 trial of masitinib for mCRPC
07 Jul 2025 18:22 GMT
… Medicines Agency (EMA) have granted authorization for a confirmatory phase 3 trial … 3 study by both the FDA and EMA represents a critical … previous treatment with abiraterone acetate (Zytiga) or who were indicated for treatment docetaxel …
-
Enrollment begins in phase 2 trial of opaganib plus darolutamide in mCRPC
02 Jul 2025 22:09 GMT
… Urogenital and Prostate Cancer Trials Group Ltd. (ANZUP) … to standard of care treatment with androgen receptor pathway … the placebo-controlled, randomized trial plans to enroll approximately … Erleada), or abiraterone acetate (Zytiga).
The study will utilize the …
-
Dr Saraiya on the AMPLITUDE Trial in mCSPC
27 Jun 2025 16:32 GMT
… combination with abiraterone acetate (Zytiga) plus prednisone (AAP) … Biren Saraiya, MD, medical oncologist at Rutgers Cancer Institute … in the MAGNITUDE trial.
Eligible patients with … and hypertension. However, treatment discontinuations due to adverse …
-
FDA Declines to Expand Label for Talazoparib/Enzalutamide in mCRPC
17 Jun 2025 20:51 GMT
… phase 3 TALAPRO-2 trial (NCT03395197) to support … included prior abirateone acetate (Zytiga) or dectaxel for … www.fda.gov/drugs/drug-approvals-and-databases/fda-approves- … (ENZA) as first-line treatment in unselected patients with metastatic …
-
ASCO 25: J&J combo pill may see wider use in prostate cancer
04 Jun 2025 15:07 GMT
… the results of a new trial convince regulators.
The AMPLITUDE study … ) with BRCA mutations, although the FDA stopped short of giving it … is still a need for treatments that are tailored to patients … from the drug.
Akeega is viewed as a successor to Zytiga, a …
-
J&J data support earlier use of combo pill in prostate cancer
03 Jun 2025 18:41 GMT
… , a pill that combines the active ingredients from the medicines Zejula and Zytiga … .
Some physicians and drugmakers have explored moving treatment to early-stage disease … that broader population,” he said.
Trial investigators also analyzed results by …
-
FDA expands darolutamide indication for advanced prostate cancer
04 Jun 2025 22:53 GMT
… trial results showed darolutamide significantly improved radiographic PFS.
The FDA … FASCO, professor of medicine and presidential endowed chair … treatments to ADT in this setting — with sister drugs … Erleada, Janssen) and abiraterone (Zytiga, Janssen) — and this …